S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
NKTR · Nektar Therapeutics
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Nektar Therapeutics (NKTR)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$38.27
-0.82
(-2.10%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$38.27
$38.27
$40.23
52-WEEK RANGE
$38.27
$33.40
$109.00
What's happening
- NKTR is down 2.10% today, trading at $38.27. — Live quote
- Volume today (28,971) is well below its 3-month average of 1,124,990. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (after market close), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.23 actual vs. $-2.02 estimated (+39.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 8
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NKTR
-7.24%
vs S&P 500
-20.01%
1-YEAR RETURN
NKTR
-37.74%
vs S&P 500
-52.30%
6-MONTH RETURN
NKTR
-53.30%
3-MONTH RETURN
NKTR
-42.89%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.23
Est. $-2.02
BEAT +39.2%
2026-04-26 (Q1 2026)
$-1.82
Est. $-1.63
MISS -11.9%
2026-01-26 (Q4 2025)
$-1.78
Est. $-2.52
BEAT +29.5%
2025-10-26 (Q3 2025)
$-1.87
Est. $-2.74
BEAT +31.7%
Valuation Measures & Ratios
Enterprise Value4$1.37B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)24.76
Price / Book72.61
EV4 / Revenue25.09
EV4 / EBITDA2.06
Profit Margin-284.39%
Operating Margin-257.80%
Return on Equity (ROE8)-37.54%
Return on Assets (ROA9)-25.45%
Avg Volume (3M)1,124,990
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.30B | $1.77B | $1.08B | $363.7M | $143.4M |
| P/E | -14.17 | -10.26 | -6.55 | -2.00 | -0.81 |
| Price/Sales | 52.41 | 40.07 | 18.77 | 5.25 | 1.80 |
| Price/Book | 2.55 | 3.08 | 12.70 | -15.02 | 10.44 |
| EV/Revenue | 51.52 | 36.69 | 18.06 | 4.63 | 1.31 |
| ROE | -18.01% | -30.01% | -193.98% | 751.29% | -1289.15% |
| ROA | -14.85% | -22.65% | -54.77% | -87.65% | -69.12% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,968,325
Change from Prior Settlement+21.49%
% of Float—
Days to Cover (Short Ratio)3.76
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -9.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -284.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -37.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NKTR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1M | $10.9M | $11.8M | $11.2M | $10.5M | $24.1M | $23.5M | $21.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$42.3M | -$39.1M | -$31.7M | -$36.2M | -$44.5M | -$34.3M | -$49.8M | -$35.4M |
| Net income | -$40.6M | -$44.9M | -$35.5M | -$41.6M | -$50.9M | -$37.1M | -$52.4M | -$36.8M |
| EPS (diluted) | $-1.23 | $-1.82 | $-1.87 | $-2.95 | $-3.62 | $-2.66 | $-3.76 | $-0.19 |
| EPS (basic) | $-1.23 | $-1.82 | $-1.87 | $-2.95 | $-3.62 | $-2.66 | $-3.76 | $-0.19 |
| Operating margin | -$418 | -$360 | -$269 | -$324 | -$426 | -$142 | -$212 | -$164 |
| Net margin | -$401 | -$413 | -$301 | -$372 | -$486 | -$154 | -$223 | -$170 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.10B | $763.3M | $280.4M | $301.3M | $207.5M | $256.2M | $303.9M | $308.0M |
| Total liabilities | $192.0M | $187.1M | $190.6M | $216.3M | $231.7M | $242.5M | $243.1M | $259.1M |
| Stockholders' equity | $903.1M | $576.2M | $89.8M | $85.1M | -$24.2M | $13.7M | $60.7M | $48.9M |
| Total current assets | $739.4M | $589.0M | $266.3M | $281.4M | $186.6M | $229.9M | $261.3M | $286.5M |
| Total current liabilities | $71.0M | $57.7M | $53.5M | $66.3M | $71.4M | $70.9M | $61.4M | $67.6M |
| Cash & equivalents | $39.3M | $149.6M | $15.1M | $41.0M | $43.0M | $38.9M | $44.3M | $30.1M |
| Accounts receivable | — | — | — | — | — | — | $0 | $0 |
| Inventory | — | — | $0 | — | — | — | $0 | $0 |
| Other current assets | $55.1M | $20.4M | $20.5M | $11.1M | $10.7M | $11.3M | $6.1M | $8.9M |
| Property, plant & equipment | — | — | $2.1M | $2.8M | $3.0M | $3.2M | $3.4M | $3.6M |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | $16.7M | $11.2M | $14.1M | $5.2M | $5.0M | $5.4M | $4.6M | $4.5M |
| Accounts payable | $24.9M | $10.0M | $10.8M | $15.6M | $14.3M | $17.8M | $11.6M | $8.6M |
| Accrued liabilities | $23.4M | $25.2M | $22.3M | $28.6M | $35.1M | $31.3M | $30.0M | $32.4M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $7.8M | $8.4M | $8.6M | $5.0M | $5.6M | $6.8M | $7.2M | $6.9M |
| Common stock & paid-in capital | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K |
| Retained earnings | -$3.85B | -$3.81B | -$3.76B | -$3.72B | -$3.69B | -$3.65B | -$3.60B | -$3.60B |
| Accumulated other comprehensive income (loss) | -$1.8M | -$1.0M | $17.0K | $56.0K | -$14.0K | $39.0K | $61.0K | $355.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.8M | -$44.3M | -$65.0M | -$48.8M | -$45.7M | -$49.1M | -$46.2M | -$43.9M |
| Investing cash flow | -$399.1M | -$350.8M | $372.0K | -$94.9M | $49.6M | $43.7M | $60.2M | $46.1M |
| Financing cash flow | $364.6M | $529.5M | $38.7M | $141.7M | $211.0K | $7.0K | $83.0K | $13.0K |
| Free cash flow | -$75.9M | -$44.3M | -$65.0M | -$48.9M | -$45.8M | -$49.1M | -$46.6M | -$44.6M |
| Capital expenditures | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K |
| Depreciation & amortization | — | — | — | — | — | — | $4.1M | — |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Deferred income taxes | — | — | $64.0K | — | — | — | $2.0K | -$31.0K |
| Change in accounts receivable | — | — | $0 | $0 | $0 | $0 | $2.2M | $850.0K |
| Change in inventory | — | — | $0 | $0 | $0 | $0 | -$1.3M | -$123.0K |
| Change in accounts payable | $15.1M | -$934.0K | -$4.8M | $1.3M | -$3.5M | $6.4M | $3.7M | $2.2M |
| Purchases of investments | $535.5M | $452.3M | $91.6M | $149.6M | $18.9M | $24.9M | $69.8M | $18.4M |
| Sales/maturities of investments | $136.4M | $101.5M | $92.0M | $54.8M | $68.6M | $69.3M | $65.1M | $65.2M |
| Share repurchases | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M |
| EPS (diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| EPS (basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| Operating margin | -$254 | -$107 | -$293 | -$409 | -$438 |
| Net margin | -$297 | -$121 | -$306 | -$400 | -$514 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.12B |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M |
| Stockholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M |
| Total current assets | $266.3M | $261.3M | $330.7M | $546.0M | $795.6M |
| Total current liabilities | $53.5M | $61.4M | $51.3M | $68.2M | $85.2M |
| Cash & equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M |
| Accounts receivable | — | $0 | $1.2M | $6.0M | $22.5M |
| Inventory | $0 | $0 | $16.1M | $19.2M | $15.8M |
| Other current assets | $20.5M | $6.1M | $9.8M | $15.8M | $23.3M |
| Property, plant & equipment | $2.1M | $3.4M | $18.9M | $32.5M | $60.5M |
| Goodwill | — | — | $0 | $76.5M | $76.5M |
| Other non-current assets | $5.6M | $4.6M | $4.6M | $2.2M | $2.7M |
| Accounts payable | $10.8M | $11.6M | $9.8M | $13.0M | $9.7M |
| Accrued liabilities | $22.3M | $30.0M | $22.2M | $36.6M | — |
| Deferred revenue (current) | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | $8.6M | $7.2M | $4.6M | $7.6M | $3.6M |
| Common stock & paid-in capital | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K |
| Retained earnings | -$3.76B | -$3.60B | -$3.48B | -$3.20B | -$2.83B |
| Accumulated other comprehensive income (loss) | $17.0K | $61.0K | $80.0K | -$6.9M | -$4.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M |
| Investing cash flow | -$1.2M | $142.6M | $139.6M | $365.8M | $202.8M |
| Financing cash flow | $180.6M | $42.1M | $30.0K | $1.5M | $36.2M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M |
| Capital expenditures | $171.0K | $1.5M | $865.0K | $5.7M | $15.0M |
| Depreciation & amortization | — | $4.1M | $7.0M | $12.2M | $13.0M |
| Share-based compensation | — | — | — | — | — |
| Deferred income taxes | $64.0K | -$10.0K | -$140.0K | $2.7M | -$102.0K |
| Change in accounts receivable | $0 | $3.0M | -$4.8M | -$16.5M | -$12.4M |
| Change in inventory | $0 | -$497.0K | -$699.0K | $3.4M | $509.0K |
| Change in accounts payable | -$625.0K | $2.7M | -$2.9M | $3.1M | -$11.7M |
| Purchases of investments | $285.0M | $261.7M | $511.7M | $467.9M | $960.7M |
| Sales/maturities of investments | $284.7M | $340.4M | $650.9M | $826.2M | $1.17B |
| Share repurchases | $0 | $3.0M | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NKTR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-11-21 to 2026-09-23
Recent transactions
- Insiders have net sold 32,466 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: WHITFIELD ROY A (Reporting person) — Grant / award of 2,000 shares on 2026-09-23.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)32,466 sh(10 txns)
Net Shares-32,466
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| WHITFIELD ROY A | Reporting person | Grant / award | 2026-09-23 | 2,000 |
| GREER R SCOTT | Reporting person | Grant / award | 2026-09-23 | 2,000 |
| CHESS ROBERT | Reporting person | Grant / award | 2026-09-23 | 2,000 |
| Brainard Diana | Reporting person | Grant / award | 2026-09-23 | 2,000 |
| Ajer Jeffrey Robert | Reporting person | Grant / award | 2026-09-23 | 2,000 |
| Zalevsky Jonathan | Chief R&D Officer | Open market sale | 2026-08-18 | 186 |
| ROBIN HOWARD W | President & CEO | Open market sale | 2026-08-18 | 418 |
| Wilson Mark Andrew | Chief Legal Officer | Open market sale | 2025-11-25 | 630 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | WHITFIELD ROY A | Reporting person | Grant / award | 2,000 | $0.00 |
| 2026-09-23 | GREER R SCOTT | Reporting person | Grant / award | 2,000 | $0.00 |
| 2026-09-23 | CHESS ROBERT | Reporting person | Grant / award | 2,000 | $0.00 |
| 2026-09-23 | Brainard Diana | Reporting person | Grant / award | 2,000 | $0.00 |
| 2026-09-23 | Ajer Jeffrey Robert | Reporting person | Grant / award | 2,000 | $0.00 |
| 2026-08-18 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 186 | $71.98 |
| 2026-08-18 | ROBIN HOWARD W | President & CEO | Open market sale | 418 | $71.98 |
| 2026-06-30 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 5,681 | $70.00 |
| 2026-06-17 | ROBIN HOWARD W | President & CEO | Open market sale | 5,500 | $60.81 |
| 2026-06-17 | ROBIN HOWARD W | President & CEO | Open market sale | 4,500 | $61.65 |
| 2026-06-16 | ROBIN HOWARD W | President & CEO | Open market sale | 5,303 | $59.97 |
| 2026-06-16 | ROBIN HOWARD W | President & CEO | Open market sale | 4,697 | $60.71 |
| 2026-06-15 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 5,538 | $60.71 |
| 2026-05-19 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 199 | $65.51 |
| 2026-05-19 | ROBIN HOWARD W | President & CEO | Open market sale | 444 | $65.51 |
| 2026-02-18 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 180 | $73.00 |
| 2026-02-18 | ROBIN HOWARD W | President & CEO | Open market sale | 423 | $73.00 |
| 2026-01-20 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 3,867 | $35.67 |
| 2025-12-22 | Zalevsky Jonathan | Chief R&D Officer | Grant / award | 6,250 | $0.00 |
| 2025-12-22 | ROBIN HOWARD W | President & CEO | Grant / award | 21,667 | $0.00 |
| 2025-11-25 | Zalevsky Jonathan | Chief R&D Officer | Open market sale | 1,157 | $54.28 |
| 2025-11-25 | Wilson Mark Andrew | Chief Legal Officer | Open market sale | 630 | $54.28 |
| 2025-11-25 | ROBIN HOWARD W | President & CEO | Open market sale | 2,207 | $54.28 |
| 2025-11-21 | Zalevsky Jonathan | Chief R&D Officer | Grant / award | 2,666 | $0.00 |
| 2025-11-21 | Wilson Mark Andrew | Chief Legal Officer | Grant / award | 1,903 | $0.00 |
| 2025-11-21 | ROBIN HOWARD W | President & CEO | Grant / award | 7,110 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:58 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-01 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-25 | 8-K | 2026-09-24 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
Recent news
Headlines about NKTR (Nektar Therapeutics). Links open the publisher — we don’t host full articles.
-
BTIG keeps USD 178 target for Nektar Therapeutics stock
AD HOC NEWS · 2026-10-20 -
Nektar Therapeutics Expands 2025 Inducement Plan by Registering Additional 250,000 Shares
Kalkine Media · 2026-10-20 -
NKTR Nov 2026 39.000 call (NKTR261120C00039000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-20 -
NKTR Nov 2026 37.000 call (NKTR261120C00037000) interactive stock chart – Yahoo Finance
Yahoo Finance Singapore · 2026-10-19 -
NKTR Nov 2026 38.000 call (NKTR261120C00038000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18 -
NKTR Nov 2026 36.000 put (NKTR261120P00036000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-18 -
Understanding the Setup: (NKTR) and Scalable Risk
Stock Traders Daily · 2026-10-18 -
Nektar Therapeutics stock trails UBS target by 32.49 percent on October 16
AD HOC NEWS · 2026-10-17
No headlines in this category right now — try “All”.